TD Cowen analyst Daniel Brennan maintained a Buy rating on Nautilus Biotechnolgy (NAUT – Research Report) yesterday. The company’s shares closed yesterday at $2.56.
According to TipRanks, Brennan is an analyst with an average return of -4.1% and a 43.95% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Danaher, Revvity, and Qiagen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nautilus Biotechnolgy with a $3.00 average price target.
See the top stocks recommended by analysts >>
NAUT market cap is currently $292.3M and has a P/E ratio of -5.01.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nautilus Biotechnolgy (NAUT) Company Description:
ARYA Sciences Acquisition Corp III is a blank check company.
Read More on NAUT:
